Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study

Schmid, P ; Cortes, J ; Dent, RA ; Pusztai, L ; McArthur, HL ; Kummel, S ; Denkert, C ; Park, YH ; Hui, R ; Harbeck, N ; Takahashi, M ; Foukakis, T ; Reynier, MAM ; Ferreira, MIR ; Im, SA ; Cardoso, F ; Ding, Y ; Pan, W ; Tryfonidis, KE ; O'Shaughnessy, J

ANNALS OF ONCOLOGY, 2023, Vol.34, p.S1257 [Periódico revisado por pares]

Texto completo disponível